Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AbbVie's acquisition of DJS Antibodies, a small UK biotech, for $255 million in cash plus milestones marks one of several recent moves to bolster the company's…
AbbVie inked a $255 million cash deal to buy DJS Antibodies, the U.K. biotech that has spent the past several years building an antibody discovery platform…
Bristol Myers Squibb reported positive Phase 2 results for BMS-986278, an oral lysophosphatidic acid receptor 1 antagonist, in patients with idiopathic…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
AbbVie acquired DJS Antibodies for ~$255M cash plus undisclosed development milestones for DJS-002. DJS's HEPTAD platform targets transmembrane proteins (e.g., GPCRs) that have been historically difficult to drug. Lead program DJS-002 is a preclinical first-in-class LPAR1 antagonist antibody for IPF. The acquisition completed in Q4 2022: DJS Antibodies Ltd is listed as a UK subsidiary in AbbVie's FY2022 Form 10-K (Exhibit 21, as of Dec 31, 2022).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / DJS Antibodies Ltd. (this deal) | 2022 | $255M | — |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2022 deals · AbbVie Inc. deals · Respiratory deals